Cargando…

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension

Optimization efforts were devoted to discover novel PDE10A inhibitors in order to improve solubility and pharmacokinetics properties for a long-term therapy against pulmonary arterial hypertension (PAH) starting from the previously synthesized inhibitor A. As a result, a potent and highly selective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Yuncong, Zhang, Sirui, Zhou, Qian, Zhang, Chen, Gao, Yuqi, Wang, Hao, Li, Zhe, Wu, Deyan, Wu, Yinuo, Huang, Yi-You, Guo, Lei, Luo, Hai-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745062/ https://www.ncbi.nlm.nih.gov/pubmed/33354505 http://dx.doi.org/10.1016/j.apsb.2020.04.003

Ejemplares similares

Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells
por: Qiu, Meiying, et al.
Publicado: (2021)

Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent
por: Shao, Yong-xian, et al.
Publicado: (2014)

Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis
por: Zhou, Qian, et al.
Publicado: (2023)

Striatal phosphodiesterase 10A availability is altered secondary to chronic changes in dopamine neurotransmission
por: Ooms, Maarten, et al.
Publicado: (2016)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

Discovery of genomic intervals that underlie nematode responses to benzimidazoles
por: Zamanian, Mostafa, et al.
Publicado: (2018)

Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities
por: Li, Jinxuan, et al.
Publicado: (2018)

Role of Phosphodiesterase 5 and Cyclic GMP in Hypertension
por: Mergia, Evanthia, et al.
Publicado: (2016)

The Use of Cyclodextrin Inclusion Complexes to Increase the Solubility and Pharmacokinetic Profile of Albendazole
por: Ding, Yili, et al.
Publicado: (2023)

Phosphodiesterase 5 Attenuates the Vasodilatory Response in Renovascular Hypertension
por: Stegbauer, Johannes, et al.
Publicado: (2013)

Structure-based discovery of orally efficient inhibitors via unique interactions with H-pocket of PDE8 for the treatment of vascular dementia
por: Wu, Xu-Nian, et al.
Publicado: (2022)

Discovery of a highly specific (18)F-labeled PET ligand for phosphodiesterase 10A enabled by novel spirocyclic iodonium ylide radiofluorination
por: Xiao, Zhiwei, et al.
Publicado: (2022)

Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents
por: Feng, Senling, et al.
Publicado: (2020)

Inhibition of phosphodiesterase 5 restores endothelial function in renovascular hypertension
por: Dias, Ananda T, et al.
Publicado: (2014)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil
por: Evans, Jeffery D, et al.
Publicado: (2015)

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease
por: Zhang, Chen, et al.
Publicado: (2017)

Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin
por: Ding, Yili, et al.
Publicado: (2023)

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: safety, tolerability, and efficacy
por: Buckley, Mitchell S, et al.
Publicado: (2010)

New Prospective Phosphodiesterase Inhibitors: Phosphorylated Oxazole Derivatives in Treatment of Hypertension
por: Nizhenkovska, Iryna V., et al.
Publicado: (2023)

1-[2,2-Bis(1,3-benzimidazol-1-ylmethyl)-3-bromopropyl]-1,3-benzimidazole
por: Wei, Tai-Bao, et al.
Publicado: (2011)

Development of Phosphodiesterase–Protein-Kinase Complexes as Novel Targets for Discovery of Inhibitors with Enhanced Specificity
por: Tulsian, Nikhil K., et al.
Publicado: (2021)

Molecular evidence of widespread benzimidazole drug resistance in Ancylostoma caninum from domestic dogs throughout the USA and discovery of a novel β-tubulin benzimidazole resistance mutation
por: Venkatesan, Abhinaya, et al.
Publicado: (2023)

Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors
por: Ovchinnikov, Artem, et al.
Publicado: (2022)

Readily Available Chiral Benzimidazoles-Derived Guanidines as Organocatalysts in the Asymmetric α-Amination of 1,3-Dicarbonyl Compounds
por: Benavent, Llorenç, et al.
Publicado: (2017)

Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease
por: Su, Tao, et al.
Publicado: (2016)

Availability, Pharmaceutics, Security, Pharmacokinetics, and Pharmacological Activities of Patchouli Alcohol
por: Hu, Guanying, et al.
Publicado: (2017)

Efficacy and safety of endothelin receptor antagonists, phosphodiesterase type 5 Inhibitors, and prostaglandins in pediatric pulmonary arterial hypertension: A network meta-analysis
por: Cao, Fen, et al.
Publicado: (2023)

Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study
por: Jiang, Miaomiao, et al.
Publicado: (2023)

(±)-1-(1H-Benzimidazol-2-yl)ethanol
por: Xia, Rong, et al.
Publicado: (2008)

Argon pharmacokinetics: a solubility measurement technique
por: Lemaire, Joël, et al.
Publicado: (2022)

Dual Photochemistry of Benzimidazole
por: Roque, José P. L., et al.
Publicado: (2023)

Synthesis of New Fluoro-Benzimidazole Derivatives as an Approach towards the Discovery of Novel Intestinal Antiseptic Drug Candidates
por: Çevik, Ulviye Acar, et al.
Publicado: (2017)

Solubility and Pharmacokinetic Profile Improvement of Griseofulvin through Supercritical Carbon Dioxide-Assisted Complexation with HP-γ-Cyclodextrin
por: Ding, Yili, et al.
Publicado: (2023)

Predictors of the response to phosphodiesterase-5 inhibitors in pulmonary arterial hypertension: an analysis of the Spanish registry
por: Garcia, Agustin R., et al.
Publicado: (2023)

Alterations in the phosphodiesterase type 5 pathway and oxidative stress correlate with erectile function in spontaneously hypertensive rats
por: He, Weixiang, et al.
Publicado: (2020)

Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study
por: Ba, Mingchen, et al.
Publicado: (2019)

Methods for the Discovery and Identification of Small Molecules Targeting Oxidative Stress-Related Protein–Protein Interactions: An Update
por: Wu, Xuexuan, et al.
Publicado: (2022)

Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia
por: Kubota, Manabu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aagqi858kjcjcqf0irqlk3ubfo